Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
HER2− breast cancer
background parenchymal enhancement
breast cancer
magnetic resonance imaging
neoadjuvant chemotherapy
tumor response
Journal
Journal of breast imaging
ISSN: 2631-6129
Titre abrégé: J Breast Imaging
Pays: United States
ID NLM: 101752190
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
19
12
2019
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
ppublish
Résumé
Women with advanced HER2- breast cancer have limited treatment options. Breast MRI functional tumor volume (FTV) is used to predict pathologic complete response (pCR) to improve treatment efficacy. In addition to FTV, background parenchymal enhancement (BPE) may predict response and was explored for HER2- patients in the I-SPY-2 TRIAL. Women with HER2- stage II or III breast cancer underwent prospective serial breast MRIs during four neoadjuvant chemotherapy timepoints. BPE was quantitatively calculated using whole-breast manual segmentation. Logistic regression models were systematically explored using pre-specified and optimized predictor selection based on BPE or combined with FTV. A total of 352 MRI examinations in 88 patients (29 with pCR, 59 non-pCR) were evaluated. Women with hormone receptor (HR)+HER2- cancers who achieved pCR demonstrated a significantly greater decrease in BPE from baseline to pre-surgery compared to non-pCR patients (odds ratio 0.64, 95% confidence interval (CI): 0.39-0.92, Among women with HER2- cancer, BPE alone demonstrated association with pCR in women with HR+HER2- breast cancer, with similar diagnostic performance to FTV. BPE predictors remained significant in multivariate FTV models, but without added discrimination for pCR prediction. This may be due to small sample size limiting ability to create subtype-specific multivariate models.
Identifiants
pubmed: 32803155
doi: 10.1093/jbi/wbaa028
pii: wbaa028
pmc: PMC7418876
doi:
Types de publication
Journal Article
Langues
eng
Pagination
352-360Subventions
Organisme : NCI NIH HHS
ID : P01 CA210961
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA132870
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA227763
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA151235
Pays : United States
Informations de copyright
© Society of Breast Imaging 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Radiology. 2012 Sep;264(3):670-8
pubmed: 22771878
Clin Pharmacol Ther. 2009 Jul;86(1):97-100
pubmed: 19440188
Eur Radiol. 2018 Nov;28(11):4705-4716
pubmed: 29736850
Magn Reson Imaging. 2013 Nov;31(9):1465-71
pubmed: 23992630
Radiology. 2011 Jul;260(1):50-60
pubmed: 21493794
J Magn Reson Imaging. 2020 Jan;51(1):43-61
pubmed: 31004391
AJR Am J Roentgenol. 2015 May;204(5):1120-4
pubmed: 25905951
Eur Radiol. 2016 Jun;26(6):1590-6
pubmed: 26382845
J Clin Oncol. 2017 Apr 1;35(10):1049-1060
pubmed: 28135148
Radiology. 2016 Apr;279(1):44-55
pubmed: 26624971
J Clin Oncol. 2019 Apr 20;37(12):954-963
pubmed: 30625040
Transl Oncol. 2015 Jun;8(3):204-9
pubmed: 26055178
BMC Bioinformatics. 2007 Sep 02;8:326
pubmed: 17764577
N Engl J Med. 2016 Jul 7;375(1):23-34
pubmed: 27406347
Radiology. 2012 Jun;263(3):663-72
pubmed: 22623692
Radiology. 2015 Sep;276(3):675-85
pubmed: 25811614
Transl Oncol. 2017 Oct;10(5):786-792
pubmed: 28806712
PLoS One. 2013 May 07;8(5):e61969
pubmed: 23667451
Breast Cancer Res Treat. 2018 Nov;172(2):487-496
pubmed: 30140962
Conf Proc IEEE Eng Med Biol Soc. 2004;2004:1667-70
pubmed: 17272023
Breast Cancer Res. 2018 Feb 9;20(1):13
pubmed: 29426360
Magn Reson Imaging Clin N Am. 2006 Aug;14(3):383-9, vii
pubmed: 17098179
Radiology. 2015 Aug;276(2):371-80
pubmed: 25965809